Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19229600 | 0.88 | DPP4 (0.43) | DPP4 | |
| SCHEMBL12417817 | 0.83 | DPP4 (0.32) | DPP4 | |
| SCHEMBL20467135 | 0.74 | DPP4 (0.41) | DPP4 | |
| SCHEMBL21147093 | 0.73 | DPP4 (0.33) | DPP4 | |
| SCHEMBL10150977 | 0.72 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL9686299 | 0.70 | DPP4 (0.53) | DPP4 | |
| SCHEMBL19679946 | 0.68 | ALOX5 (0.39) | — | |
| SCHEMBL20412243 | 0.67 | — | — | |
| SCHEMBL2737323 | 0.67 | WRN (0.41) | — | |
| SCHEMBL13981501 | 0.65 | CYP2E1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906900-B2 | Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-02-02 | — | — | US | disclosed |
| US-20190211011-A1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906900-B2 | Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases | PSEN2, CLN6, MAPT | DPP4 2443/4885 |
| US-20190211011-A1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | PSEN2, SNCA, MAPT | DPP4 2342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.